- Home
- ITRG vs GALT Comparison
ITRG vs GALT Comparison
Compare ITRG & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | GALT |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.9M | 397.3M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ITRG | GALT |
|---|---|---|
| Price | $2.24 | $3.16 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 182.0K |
| Earning Date | 11-11-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.41 | N/A |
| Revenue Next Year | $26.85 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $2.03 |
| 52 Week High | $4.87 | $7.13 |
Technical Indicators
Market Signals| Indicator | ITRG | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 36.11 |
| Support Level | $2.00 | $2.71 |
| Resistance Level | $2.30 | $3.30 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 46.27 | 17.50 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.